Delores Dotson, MD
Family Medicine · Hazelwood, MONPI 1881723062
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Lilly USA, LLC at 30.1% of the total. Reporting peaked in 2019 at $331 and has fallen 95.5% since, to $15 in 2024. That places this record below the midpoint for family medicine clinicians in MO, where the typical reported total is $366.
Across 25 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$115
- Boehringer Ingelheim$105
- Sanofi-aventis U.S. LLC$59
- Johnson & Johnson$45
- Bristol Myers Squibb$19
- Exact Sciences$15
- plus $24 from 2 others
Across 9 payments — averaging $12,143 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$100K
- Chiasma, Inc.$6K
- Amryt Pharma Holdings Ltd$3K
What the payments were for
- Food & beverage$37498%
- Education$82%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $115 |
| Boehringer Ingelheim | 7 | $105 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| Johnson & Johnson | 3 | $45 |
| Bristol Myers Squibb | 1 | $19 |
| Exact Sciences | 1 | $15 |
| AstraZeneca | 1 | $12 |
| Novo Nordisk | 1 | $12 |
How this compares
$382 in reported general payments places this provider in the 50th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $53,536 |
| EliquisApixaban | 42 | $46,720 |
| JardianceEmpagliflozin | 40 | $39,894 |
| TrulicityDulaglutide | 25 | $35,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $27,748 |
| Spiriva RespimatTiotropium Bromide | 28 | $25,723 |
| LinzessLinaclotide | 23 | $16,605 |
| MounjaroTirzepatide | 13 | $16,280 |
| XareltoRivaroxaban | 13 | $11,809 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 48 | $11,328 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,543 |
| Varenicline Tartrate | 19 | $5,207 |
| Atrovent HfaIpratropium Bromide | 11 | $5,107 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $3,873 |
| Famotidine | 78 | $3,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $105 | $65,61668 claims |
| Novo NordiskOzempic | $12 | $53,53647 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $115 | $51,92938 claims |
| Johnson & JohnsonXarelto | $45 | $11,80913 claims |
| AstraZenecaSymbicort | $12 | $7,54321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Hazelwood
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.